Editas Medicine

RSS Feed
Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. The company has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats (CRISPR) technology. The company is developing both in vivo CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with the company's technology and then administered to the patient. In ocular diseases, the company's program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10.
  • TickerEDIT
  • ISINUS28106W1036
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: April 3, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADV ...
9d 05/04/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 27, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADV ...
18d 27/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 20, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADC ...
24d 21/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 13, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
Personal & Household Goods
XXII , ADT ...
31d 14/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Daily Ratings Report: March 5, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
Real Estate
AMH , BASI ...
38d 07/03/2021 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Health Care
AGIO , ABTX ...
1y 19/12/2019 31 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

MSCI ACWI, STOXX 600 Breaking Out The market continues to feed off of optimism surrounding the US-China “phase one” trade deal. Boris Johnson's UK election victory has added an additional tailwind, particularly in the UK and Europe, where the UK's FTSE 250 and the STOXX Europe 600 indexes are breaking out to all-time highs. At some point the euphoria is likely to wear off, but with continued global bullish developments, it remains our belief that pullbacks should be bought and that global equities are in the early stages of a broad-based advance. • Sector Relative Strength Rankings (RS...

EUR 209.00
Chart
Health Care
ACAD , AMD ...
1y 19/12/2019 46 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Health Care
AGIO , AKBA ...
1y 12/12/2019 39 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Industrial Goods & Services
ALSN , AEL ...
1y 07/12/2019 37 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Technology
AEIS , AGLE ...
1y 31/07/2019 30 EN
SmartInsider

Editas Medicine Inc: 1 director bought

A director at Editas Medicine Inc bought 5,800 shares at 45.512USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

EUR 8.36
Corporate Voice
Health Care
Editas Medicine
39d 06/03/2021 1 EN
GlobeNewsWire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2020. Conference Call & Webcast DetailsDate:Thursday, February 25, 2021 Time:8:00 am Eastern TimeToll Free:(844) 348-3801International:(213) 358-0955Conference ID:71...

Free
Corporate Voice
Health Care
Editas Medicine
54d 18/02/2021 1 EN
GlobeNewsWire

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021 CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of the Company’s Board of Directors. “On behalf of the entire Board, I thank Cindy for her tremendous contributions and dedication to Editas Medicine,” said ...

Free
Corporate Voice
Health Care
Editas Medicine
65d 08/02/2021 1 EN
GlobeNewsWire

Editas Medicine Announces Pricing of Offering of Common Stock

Editas Medicine Announces Pricing of Offering of Common Stock CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $231.0 million. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,00...

Free
Corporate Voice
Health Care
Editas Medicine
83d 21/01/2021 1 EN
GlobeNewsWire

Editas Medicine Announces Offering of Common Stock

Editas Medicine Announces Offering of Common Stock CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine. J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen ...

Free
Corporate Voice
Health Care
Editas Medicine
84d 19/01/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: April 3, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADV ...
9d 05/04/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 27, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADV ...
18d 27/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 20, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
ADT , ADC ...
24d 21/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Weekly Tables: March 13, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
Personal & Household Goods
XXII , ADT ...
31d 14/03/2021 1 EN
InsiderInsights.com
Jonathan Moreland

InsiderInsights Daily Ratings Report: March 5, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

EUR 8.36
Equity
Real Estate
AMH , BASI ...
38d 07/03/2021 1 EN
TheScreener

EDITAS MEDICINE sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of EDITAS MEDICINE (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 26, 2021, the closing price was USD 60.68 and its target price was estimated at USD 36.60.

EUR 12.54
Quant
Health Care
Editas Medicine
77d 27/01/2021 6 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch